

Table 2. Detailed Characteristics of Antidepressive Agent Studies Included in the Meta-Analysis (n = 8)

#	Study (First Author, Year)	Country	Population Description	Mean Age	Sample Size	Intervention Details	Duration (weeks)	Frequency (sessions/week)	Follow-up Timepoints	Depression Outcome (Measure)
1	Brenes et al.(2007)	USA	Older adults (~70 yrs) with minor depression (DSM-IV), community-dwelling	75.6	42/42	Sertraline	16	Sertraline dose not specified	Baseline & 16 weeks	DS↓; PF↑: Improvements observed in both HAM-D and SF-36 mental health scores.
2	Schneider et al.(2003)	USA	Outpatients ≥ 60 yrs with DSM-IV major depression, HAM-D ≥ 18	75.25	14/18	Flexible-dose sertraline (50 or 100 mg daily) vs placebo	8	50–100 mg/day	End of 8 weeks	DS↓; CGI↑; RT↓: HAM-D score reduction (7.4 vs 6.6); 45% responders vs 35% in placebo; shorter time to sustained response (57 vs 61 days).
3	Roose et al.(2004)	USA	Community-dwelling adults aged ≥ 75 yrs with unipolar depression	76.42	19/20	Citalopram (SSRI) 10–40 mg/day vs placebo	8	10–40 mg/day	End of 8 weeks	DS↓; RR↑: Remission rates (HAM-D <10): 35% vs 33%, not significant; strong placebo effects observed in older adults.
4	Tollefson et al.(1995)	USA	Outpatients ≥ 60 yrs with major depression (nonpsychotic)	69.73	18/24	Fluoxetine 20 mg/day vs placebo	6	20 mg/day	End of 6 weeks	DS↓: Response rate 43.9% vs 31.6% (p = .002); remission rate 31.6% vs 18.6% (p < .001).
5	Rapaport et al.(2003)	USA	Older adults with MDD (controlled-release paroxetine)	69.19	27/29	Paroxetine CR (dose NR) vs placebo	8	NR	8 weeks	DS↓: Significant improvements in HAM-D and CGI scores (p < .05).
6	Parnetti et al.(1993)	Italy	Elderly outpatients with prolonged depressive reaction	76.1	29/25	Minaprine vs placebo (double-blind)	6	NR	6 weeks	DS↓: Significant HAM-D reduction compared to placebo (p < .05).
7	Lyketsos et al.(2003)	USA	Alzheimer's patients ≥65 yrs with depression	77.6	33/30	Sertraline (dose NR) vs placebo	12	NR	12 weeks	DS↓; BD↓: Reduced depressive and behavioral disturbances, improved sleep and agitation; improvement in HAM-D symptoms.

8	Nelson et al.(2005)	USA	Adults $\geq$ 65 yrs with MDD	79.15	59/55	Duloxetine 60 mg/day vs placebo	12	60 mg/day	12 weeks	DS↓; PS↓: Significant improvement in HAM-D and pain symptoms; higher response rate in the treatment group.
---	---------------------	-----	-------------------------------	-------	-------	------------------------------------	----	-----------	----------	--

DS: Depression Symptoms; PF: Physical Functioning; CGI: Cgi-Defined Response Rate; RT: Response Time; RR: Remission Rate; BD: Behavior Disturbance; PS: Pain Symptoms ↑: Increase/Enhance/Raise; ↓: Decrease/Alleviate/Lower; ×: Unaffected/No Significant Chang